LC-MS-based metabolomics in understanding the mechanisms of alzheimer's disease and biomarker discovery

Advanced LC-MS Applications in Metabolomics

Volumn , Issue , 2015, Pages 40-57

  Trushina, Eugenia ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BIOMOLECULES; DIAGNOSIS; METABOLISM; METABOLITES; NEURODEGENERATIVE DISEASES;

ALZHEIMER'S DISEASE; BIO-MARKER DISCOVERY; CELLULAR PATHWAY; METABOLIC FINGERPRINTS; METABOLIC NETWORK; METABOLIC PATHWAYS; MILD COGNITIVE IMPAIRMENTS; TRANSLATIONAL RESEARCH;

BIOMARKERS;

EID: 84957388486     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781910419441.fseb2013.13.71     Document Type: Chapter

References (28)

1. Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer's disease. Biochim. Biophys. Acta, 1842, (8), 1232-1239 (2013).
2. Kaddurah-Daouk R, Rozen S, Matson W et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement. 7(3), 309-317 (2011).
3. Kaddurah-Daouk R, Zhu H, Sharma S et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl. Psychiatry 3, e244 (2013).
4. Czech C, Berndt P, Busch K et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One 7(2), e31501 (2012).
5. Sato Y, Nakamura T, Aoshima K, Oda Y. Quantitative and wide-ranging profiling of phospholipids in human plasma by two-dimensional liquid chromatography/mass spectrometry. Anal. Chem. 82(23), 9858-9864 (2010).
6. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J. Lipid Res. 53(3), 567-576 (2012).
7. Chan RB, Oliveira TG, Cortes EP et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287(4), 2678-2688 (2012).
8. Han X, Rozen S, Boyle SH et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6(7), e21643 (2011).
9. Ibanez C, Simo C, Martin-Alvarez PJ et al. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal. Chem. 84(20), 8532-8540 (2012).
10. Ibanez C, Simo C, Barupal DK et al. A new metabolomic workflow for early detection of Alzheimer's disease. J. Chromatogr. A, 1302, 65-71 (2013).
11. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 8(5), e63644 (2013).
12. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30(7), 1235-1239 (2009).
13. Oresic M, Hyotylainen T, Herukka SK et al. Metabolome in progression to Alzheimer's disease. Transl. Psychiatry 1, e57 (2011).
14. Li NJ, Liu WT, Li W et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43(12), 992-997 (2010).
15. Inoue K, Tsutsui H, Akatsu H et al. Metabolic profiling of Alzheimer's disease brains. Sci. Rep 3, 2364 (2013).
16. Astarita G, Jung KM, Vasilevko V et al. Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. PLoS One 6(10), e24777 (2011).
17. Hejazi L, Wong JW, Cheng D et al. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem. J. 438(1), 165-175 (2011).
18. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 32(2), 213-224 (2007).
19. Marjanska M, Curran GL, Wengenack TM et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA 102(33), 11906-11910 (2005).
20. von Kienlin M, Kunnecke B, Metzger F et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 18(1), 32-39 (2005).
21. Salek RM, Xia J, InnesA et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 56(8), 937-947 (2010).
22. Lalande J, Halley H, Balayssac S et al. 1H NMR metabolomic signatures in five brain regions of the AbetaPPswe Tg2576 mouse model of Alzheimer's disease at four ages. J. Alzheimers Dis. 39(1), 121-143 (2014).
23. Chen SQ, Cai Q, Shen YY et al. Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Behav. Brain Res. 235(1), 1-6 (2012).
24. Trushina E, Nemutlu E, Zhang S et al. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7(2) (2012).
25. Chen SQ, Cai Q, Shen YY et al. (1)H-MRS evaluation of therapeutic effect of neural stem cell transplantation on Alzheimer's disease in AbetaPP/PS1 double transgenic mice. J. Alzheimers Dis. 28(1), 71-80 (2012).
26. Westman E, Spenger C, Oberg J, Reyer H, Pahnke J, Wahlund LO. In vivo1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci. 10, 33 (2009).
27. Tajima Y, Ishikawa M, Maekawa K et al. Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis. 12, 68 (2013).
28. Marquardt G, Currier R, McHugh DM et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet. Med. 14(7), 648-655 (2012).